158 reports of this reaction
1.0% of all EMICIZUMAB reports
#20 most reported adverse reaction
HAEMATOMA is the #20 most commonly reported adverse reaction for EMICIZUMAB, manufactured by Genentech, Inc.. There are 158 FDA adverse event reports linking EMICIZUMAB to HAEMATOMA. This represents approximately 1.0% of all 15,224 adverse event reports for this drug.
Patients taking EMICIZUMAB who experience haematoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATOMA is a less commonly reported adverse event for EMICIZUMAB, but still significant enough to appear in the safety profile.
In addition to haematoma, the following adverse reactions have been reported for EMICIZUMAB:
The following drugs have also been linked to haematoma in FDA adverse event reports:
HAEMATOMA has been reported as an adverse event in 158 FDA reports for EMICIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATOMA accounts for approximately 1.0% of all adverse event reports for EMICIZUMAB, making it a notable side effect.
If you experience haematoma while taking EMICIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.